Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Acute febrile neutrophilic dermatosis, Biopsy, Sarcoidosis
Clinical narrative: This literature-non-study case was reported in a literature article and describes the occurrence of SARCOIDOSIS (Sarcoidal reaction with a Sweet-like phenomenon) and ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (Sarcoidal reaction with a Sweet-like phenomenon) in a 38-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. LITERATURE REFERENCE: An acute, ulcerative, Sarcoidal tattoo reaction following SARS-CoV-2 mRNA-1273 vaccination. Dermatol Online J. 2021;27(12):12. No Medical History information was reported. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced SARCOIDOSIS (Sarcoidal reaction with a Sweet-like phenomenon) (seriousness criterion medically significant) and ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (Sarcoidal reaction with a Sweet-like phenomenon) (seriousness criterion medically significant). The patient was treated with CLOBETASOL PROPIONATE (CLOBETASOL 0.05%) (topical) for Adverse event, at a dose of UNK UNK, BID. At the time of the report, SARCOIDOSIS (Sarcoidal reaction with a Sweet-like phenomenon) and ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (Sarcoidal reaction with a Sweet-like phenomenon) was resolving. Related DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Biopsy: Sarcoidal granulomas and a dense revealed Sarcoidal granulomas and a dense neutrophilic infiltrate. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered SARCOIDOSIS (Sarcoidal reaction with a Sweet-like phenomenon) and ACUTE FEBRILE NEUTROPHILIC DERMATOSIS (Sarcoidal reaction with a Sweet-like phenomenon) to be related. Patient developed acute-onset pain and ulceration within a tattoo on the distal left leg after the first dose. Approximately one week after the second dose ulceration became progressive. After receiving the treatment for two weeks, Patient's pain was reduced and re-epithelialization of the ulcers occurred. Concomitant medications were not reported. Company comment: This literature non-study case concerns a 38-year-old female patient with no medical history reported, who experienced the unexpected serious (medically significant) events Sarcoidosis and Acute febrile neutrophilic dermatosis, on an unspecified date after the second dose of mRNA-1273 vaccine. The patient experienced, acute-onset pain and ulceration within a tattoo on the distal left leg after the first dose. Approximately one week after the second dose ulceration became progressive. After receiving the treatment (not specified) for two weeks, Patient's pain reduced, and re-epithelialization of the ulcers occurred. Biopsy: Sarcoidal granulomas and a dense neutrophilic infiltrate. At the time of report, the events were resolving. The benefit-risk relationship of mRNA-1273 is not affected by this report. Sender's Comments: This literature non-study case concerns a 38-year-old female patient with no medical history reported, who experienced the unexpected serious (medically significant) events Sarcoidosis and Acute febrile neutrophilic dermatosis, on an unspecified date after the second dose of mRNA-1273 vaccine. The patient experienced, acute-onset pain and ulceration within a tattoo on the distal left leg after the first dose. Approximately one week after the second dose ulceration became progressive. After receiving the treatment (not specified) for two weeks, Patient's pain reduced, and re-epithelialization of the ulcers occurred. Biopsy: Sarcoidal granulomas and a dense neutrophilic infiltrate. At the time of report, the events were resolving. The benefit-risk relationship of mRNA-1273 is not affected by this report.